To confirm the role of IFN in limiting the replication of the NS1 revertant viruses, we treated equine cells 24 h prior to infection (MOI, 0.1) with ruxolitinib (Selleck Chemicals) to block the JAK/STAT pathway and thus impaired the ability of the cells to respond to IFN (25). The gene discussed is SOAT1; the disease is infection.